An interventional study of proton beam therapy in Prostate Adenocarcinoma, sponsored by National Cancer Center, Korea. Completed at 1 site in South Korea. Open to male participants. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by National Cancer Center, Korea · Not applicable, Interventional, and Treatment
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
National Cancer Center, Korea is the lead sponsor of 203 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2 Signed study specific informed consent prior to study entry
Exclusion Criteria:
Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
Radiation: proton beam therapy
27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
Radiation: proton beam therapy
27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
Radiation: proton beam therapy
27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
Radiation: proton beam therapy
hypofractionation study using proton beam therapy for prostate adenocarcinoma
clinical outcomes
To evaluate biochemical failure-free survival (BCFFS)
Time frame: up to 5years from a initial follow-up
acute toxicity
to evaluate acute toxicities by CTCAE version 3.0
Time frame: up to 5years from a initial follow-up
late toxicity
to evaluated late toxicities by CTCAE version 3.0
Time frame: up to 5years from a initial follow-up
overall survival
to evaluated overall survival
Time frame: up to 5years from a initial follow-up
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Center, Korea →